The Vanguard Group, Inc. has recently announced that it has increased stake in Biocryst Pharmaceuticals Inc. (NASDAQ:BCRX) by 2.08%. After grabbing 14.9 million shares, the institutional investor is now in possession of 0.3 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 7.28% having worth around $87.61 million. Moreover, BlackRock Fund Advisors increased its share by 0.7 million to have a control over 14.27 million shares. And Braidwell LP raised its holdings to 2.57 million shares by acquiring 5.36 million shares or 2.62% of the stake.
Biocryst Pharmaceuticals Inc. (BCRX) concluded trading on 12/27/23 at a closing price of $6.19, with 2.92 million shares of worth about $18.05 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -13.31% during that period and on Wednesday the price saw a gain of about 1.81%. Currently the company’s common shares owned by public are about 204.81M shares, out of which, 198.47M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 12 analysts are covering the BCRX stock and their offered price forecasts bring an average price target of $14.09. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $30.00 and could fall to a lowest price of $6.00. The stock’s current price level is 56.07% above of average price target set by the analysts, while a rise to estimated low would result in loss of -3.17% for the stock. However, touching the estimated high of $30.00 would mean a gain of 79.37% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 30 times over the past 12 months. They bought 332,607 shares in 24 of the transactions. In 6 selling transactions, insiders dumped 158,866 shares.
SPDR S&P Biotech ETF, Vanguard Total Stock Market ETF, and iShares Russell 2000 ETF are the top 3 mutual funds which are holding stakes in Biocryst Pharmaceuticals Inc. SPDR S&P Biotech ETF is currently holding 7.1 million shares of worth totaling $41.75 million. The company recently came buying 33090.0 shares which brought its stake up to 3.47% of the company’s outstanding shares. Vanguard Total Stock Market ETF bought 15580.0 shares, after which its hold over company’s outstanding shares expand to 2.90%, leaving 5.94 million shares with the mutual fund that have a worth of about $34.95 million. iShares Russell 2000 ETF, after buying 4.6 million shares, have now control over 2.25% of the stake in the company. It holds 2262.0 shares of worth $27.04 million.
Stock saw a price change of 2.31% in past 5 days and over the past one month there was a price change of 16.35%. Year-to-date (YTD), BCRX shares are showing a performance of -46.08% which decreased to -45.94% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.82 but also hit the highest price of $12.07 during that period. The average intraday trading volume for Biocryst Pharmaceuticals Inc. shares is 3.85 million. The stock is currently trading 5.06% above its 20-day simple moving average (SMA20), while that difference is up 9.16% for SMA50 and it goes to -12.90% lower than SMA200.
The Vanguard Group, Inc. acquired 14.9 million shares of Biocryst Pharmaceuticals Inc. having value of about $87.61 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 0.3 million shares in the company valued at close to $1877259.87, or have control over 2.08% stake in the company. Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) currently have 204.81M outstanding shares and institutions hold larger chunk of about 85.51% of that. Holding of mutual funds in the company is about 32.89% while other institutional holders and individual stake holders have control over 52.65% and 11.80% of the stake respectively.
The stock has a current market capitalization of $1.27B and its 3Y-monthly beta is at 1.89. It has posted earnings per share of -$1.25 in the same period. It has Quick Ratio of 5.21. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BCRX, volatility over the week remained 4.60% while standing at 6.92% over the month.
Analysts are in expectations that Biocryst Pharmaceuticals Inc. (BCRX) stock would likely to be making an EPS of -$0.24 in the current quarter, while forecast for next quarter EPS is -$0.23 and it is -$0.69 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.38 which is -$0.14 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.38 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 21.35% while it is estimated to increase by 31.25% in next year. EPS is likely to grow at an annualized rate of 44.80% for next 5-years, compared to annual growth of -11.25% made by the stock over the past 5-years.
Analysts at 12 brokerage firms have issued recommendations for the Biocryst Pharmaceuticals Inc. (BCRX)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.33. Out of those 12 Wall Street analysts, 10 recommended a “Buy” rating, while 2 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JP Morgan on November 20, 2023 offering an Overweight rating for the stock and assigned a target price of $10 to it.
